Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.

Abstract excerpt

The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing life expectancy and the approval of the highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor. With that being said, the progressive pulmonary decline and importance of lung health, infection, and inflammation in CF remains. This review is the second part in a three-part CF Year in Review 2020. Part...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminophenols
• Share to Benzodioxoles
• Share to Child